| Ytd | -29.36% | |
| 1y | 36.61% |
| Open | 57.25 | Prev Close | 57.26 | Low | 56.31 | High | 58.49 | Mkt Cap | 2.46B |
| Vol | 83.26K | Avg Vol | 959.12K | EPS | -1.14 | P/E | -50.23 | Forward P/E | 106.38 |
| Beta | 0.50 | Short Ratio | 7.85 | Inst. Own | 109.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 61.68 | 200-d Avg | 69.01 | 1yr Est | 94.56 |
TARS News
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., addi
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc.,
Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the dea
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS)
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. Th
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today a
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Tr
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zac
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more th
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), toda
Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TAR
Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis,
Capricorn Fund Managers Ltd lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
Friday's session saw 466 companies set new 52-week highs.